https://www.selleckchem.com/products/butyzamide.html ariants in the absence of LFS phenotypes will define how surveillance and clinical management of these individuals should be performed. Injection of a topical anaesthetic has been proved to be helpful with reducing pain after laparoscopic herniorrhaphy. We aimed to assess the effect of bupivacaine lavage on postoperative pain and compare it with diclofenac suppository. In this randomized clinical trial, 60 patients-scheduled for laparoscopic herniorrhaphy-were enrolled and randomized into three groups of 20 each, including diclofenac suppository, bupivacaine lavage, and normal saline as a placebo.The patients were investigated for postoperative pain scores, vomiting, nausea, morphine request, and duration of hospitalization. In the bupivacaine group, pain levels in recovery room, 4, 8 and 12h after surgery, were significantly lower than diclofenac group; at time points of 16, 20 and 24h after surgery, difference between two groups was not significant. Regarding vomiting and nausea, at time points of 1 and 3h after surgery, results show no significant difference between the groups. Incident of infection, 1h and 1week after the surgery, wasin patients undergoing laparoscopic herniorrhaphy. Trial Registration Randomized clinical trial IRCT20180522039782N2; date of registration14/10/2018. Colon cancer is one of the most common cancer worldwide and has a poor prognosis. Through the analysis of transcriptome and clinical data of colon cancer, immune gene-set signature was identified by single sample enrichment analysis (ssGSEA) scoring to predict patient survival and discover new therapeutic targets. To study the role of immune gene-set signature in colon cancer. First, RNASeq and clinical follow-up information were downloaded from The Cancer Genome Atlas (TCGA). Immune gene-related gene sets were collected from ImmPort database. Genes and immunological pathways related to prognosis were screened in the training set and